scholarly journals Risperidone-induced adverse drug reactions and role of DRD2 (−141 C Ins/Del) and 5HTR2C (−759 C>T) genetic polymorphisms in patients with schizophrenia

2017 ◽  
Vol 8 (1) ◽  
pp. 28 ◽  
Author(s):  
DeepakGopal Shewade ◽  
CharanrajGoud Alladi ◽  
Anbarasan Mohan ◽  
RaviPhilip Rajkumar ◽  
Surendiran Adithan ◽  
...  
Keyword(s):  
Genetic Polymorphisms ◽  
Adverse Drug Reactions ◽  
Drug Reactions

scholarly journals Adverse Drug Reactions Among Patients Enrolled in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program 2015–2016 at UNC Medical Center

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S341-S341
Author(s):  
Vahini Chundi ◽  
Anh Eichholz ◽  
Onyeka Nwankwo ◽  
Alan Kinlaw ◽  
Wesley Kufel ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Medical Center ◽  
Critical Role ◽  
Drug Reactions ◽  
Health Records ◽  
Outpatient Parenteral Antimicrobial Therapy ◽  
Initial Cohort ◽  
Recorded Data ◽  
Antimicrobial Regimen

Abstract Background The UNC Medical Center OPAT program was started in 2015 to provide multidisciplinary monitoring and management of patients discharged on parenteral antimicrobials. We examined characteristics of incident adverse drug reactions (ADRs) observed in our initial cohort of OPAT patients. Methods We abstracted electronic health records for the first 250 patients enrolled in the OPAT program. 223 patients with sufficient recorded data for entire OPAT course were included in the analysis. ADRs meeting criteria as detailed in Table 1 were collected and further stratified by antimicrobial regimen. Results 57 patients (26%) experienced at least one ADR during OPAT therapy. The frequency of specific ADRs associated with OPAT therapies are provided in Figure 1. Β-lactam regimens were most frequently associated with liver dysfunction, while combinations of β-lactams and vancomycin were associated with kidney dysfunction. Median days on OPAT regimen was 19 days (IQR: 10–29) for patients who experienced an ADR compared with 39 (IQR: 30–44) for patients who did not experience an ADR. Conclusion ADRs were most commonly observed within the first three weeks of therapy, particularly for patients receiving vancomycin and a β-lactam antimicrobial in combination. These results underscore the critical role of a multidisciplinary team in providing laboratory monitoring and response to abnormal results for OPAT patients. In addition, closer monitoring within the first three weeks of therapy may provide opportunities for regimen changes or dose adjustment to avoid toxicities. Disclosures All authors: No reported disclosures.

The role of pharmacogenomics in adverse drug reactions

2019 ◽  
Vol 12 (5) ◽  
pp. 407-442 ◽  
Author(s):  
Ramón Cacabelos ◽  
Natalia Cacabelos ◽  
Juan C. Carril
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Reactions

scholarly journals Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents

Biosensors ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 202
Author(s):  
Rosario Iemmolo ◽  
Valentina La Cognata ◽  
Giovanna Morello ◽  
Maria Guarnaccia ◽  
Mariamena Arbitrio ◽  
...  
Keyword(s):  
Genetic Polymorphisms ◽  
Adverse Drug Reactions ◽  
Limit Of Detection ◽  
Chemotherapeutic Agents ◽  
Clinical Diagnostics ◽  
Individual Risk ◽  
Chip Assay ◽  
Drug Reactions ◽  
Lab On Chip ◽  
On Chip

Background: Antineoplastic agents represent the most common class of drugs causing Adverse Drug Reactions (ADRs). Mutant alleles of genes coding for drug-metabolizing enzymes are the best studied individual risk factors for these ADRs. Although the correlation between genetic polymorphisms and ADRs is well-known, pharmacogenetic tests are limited to centralized laboratories with expensive or dedicated instrumentation used by specialized personnel. Nowadays, DNA chips have overcome the major limitations in terms of sensibility, specificity or small molecular detection, allowing the simultaneous detection of several genetic polymorphisms with time and costs-effective advantages. In this work, we describe the design of a novel silicon-based lab-on-chip assay able to perform low-density and high-resolution multi-assay analysis (amplification and hybridization reactions) on the In-Check platform. Methods: The novel lab-on-chip was used to screen 17 allelic variants of three genes associated with adverse reactions to common chemotherapeutic agents: DPYD (Dihydropyrimidine dehydrogenase), MTHFR (5,10-Methylenetetrahydrofolate reductase) and TPMT (Thiopurine S-methyltransferase). Results: Inter- and intra assay variability were performed to assess the specificity and sensibility of the chip. Linear regression was used to assess the optimal hybridization temperature set at 52 °C (R2 ≈ 0.97). Limit of detection was 50 nM. Conclusions: The high performance in terms of sensibility and specificity of this lab-on-chip supports its further translation to clinical diagnostics, where it may effectively promote precision medicine.

CP-227 Risk minimisation of adverse drug reactions: Role of the pharmacist

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A100.2-A100
Author(s):  
M Benabbes ◽  
M Alami Chentoufi ◽  
B Meddah
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Reactions ◽  
Risk Minimisation
Sign in / Sign up

Export Citation Format

Share Document